How AI and Synthetic Patient Data are Revolutionizing Avène’s New Skincare Trials

Pierre Fabre Laboratories is pioneering a new generation of clinical studies by using Artificial Intelligence to scale patient data from 100 to 600 subjects. This innovative approach evaluates Avène Cleanance Comedomed+ as a high-precision maintenance treatment for severe acne, bridging the gap between medical prescription and daily dermo-cosmetic care.

The AI Revolution: Scaling Clinical Robustness

In a partnership with the HealthTech firm BotDesign, Avène has become the first brand to integrate AI-driven data augmentation into dermo-cosmetic clinical trials. The 2026 study focuses on adults suffering from severe to very severe acne, specifically during the maintenance phase following oral isotretinoin treatment.

The core innovation lies in the use of synthetic patient data. By virtually adding up to 500 additional subjects particularly in the placebo arm, Avène is significantly strengthening the statistical power and reliability of its results.

“We belong to a group that has always been rooted in pharmaceuticals and dermo-cosmetics. Our medical expertise gives us a head start in understanding patients and their pathologies. We are ideally positioned to offer treatment protocols based on the pathology, combining dermo-cosmetics with medication. We are already preparing solutions to go further, by developing dermo-cosmetic innovations capable of extending and amplifying the action of the medication or delaying its necessity. Because these are dermo-cosmetics, they can be used over the long term, unlike many drug treatments”.

Gautier Doat – Eau Thermale Avène Medical Director

Key Factors of the 2026 Initiative:

• Enhanced Data Pools: Scaling studies from a standard 100-patient group to a robust 600-patient dataset via AI.
• “Supportive Care” Strategy: Part of a broader mission to develop dermo-cosmetics that amplify medication or delay the need for heavy drug treatments.
• Targeted Efficacy: Evaluating Cleanance Comedomed+, which is enriched with Comedoclastin™ to target blemishes at the root.
• Timeline: Final results from this AI-augmented study are scheduled for presentation in December 2026.

As the global skincare market shifts toward “Medicalized Wellness,” clinical proof has become the ultimate luxury currency. While most competitors still rely on standard consumer perception tests, Pierre Fabre’s use of synthetic data sets a new industry standard for precision dermatology. This aligns with a global trend where AI is the core R&D engine, similar to recent AI drug discovery alliances seen in oncology.

Trivia: Avène’s parent, Pierre Fabre Laboratories, is a unique French foundation-owned group, meaning a significant portion of its profits is reinvested back into global health and R&D.

UDHQ Take: The AI-driven study of Cleanance Comedomed+ represents the “Digitalization of Wellness.” For the modern consumer, luxury is no longer defined by brand name alone but by the clinical certainty of the outcome. By integrating AI into dermo-cosmetic research, Pierre Fabre is ensuring that personal care moves beyond the anecdotal to the scientifically absolute.

This transition allows for a more personalized and effective skincare regimen, providing a “Medicalized Serenity” that addresses complex skin challenges with the same precision as high-end medical treatments. It makes a difference in your life by replacing trial-and-error with a regimen backed by data from 600 patients instead of 100, providing the ultimate reliability for sensitive, post-treatment skin.

Source: Pierre Fabre